RT Journal Article
SR Electronic
T1 Forecasting the spread of COVID-19 pandemic in Bangladesh using ARIMA model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.22.20217414
DO 10.1101/2020.10.22.20217414
A1 Kundu, Lakshmi Rani
A1 Ferdous, Most. Zannatul
A1 Islam, Ummay Soumayia
A1 Sultana, Marjia
YR 2020
UL http://medrxiv.org/content/early/2020/10/26/2020.10.22.20217414.abstract
AB Background COVID-19 is one of the most serious global public health threats creating an alarming situation. Therefore, there is an urgent need for investigating and predicting COVID-19 incidence to control its spread more effectively. This study aim to forecast the expected number of daily total confirmed cases, total confirmed new cases, total deaths and total new deaths of COVID-19 in Bangladesh for next 30 days.Methods The number of daily total confirmed cases, total confirmed new cases, total deaths and total new deaths of COVID-19 from 8 March 2020 to 16 October, 2020 was collected to fit an Autoregressive Integrated Moving Average (ARIMA) model to forecast the spread of COVID-19 in Bangladesh from 17th October 2020 to 15th November 2020. All statistical analyses were conducted using R-3.6.3 software with a significant level of p< 0.05.Results The ARIMA (0,2,1) and ARIMA (0,1,1) model was adopted for forecasting the number of daily total confirmed cases, total deaths and total confirmed new cases, new deaths of COVID-19, respectively. The results showed that an upward trend for the total confirmed cases and total deaths, while total confirmed new cases and total new death, will become stable in the next 30 days if prevention measures are strictly followed to limit the spread of COVID-19.Conclusions The forecasting results of COVID-19 will not be dreadful for upcoming month in Bangladesh. However, the government and health authorities should take new approaches and keep strong monitoring of the existing strategies to control the further spread of this pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no funding opportunity to conduct the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As all data were obtained from secondary data collection source, no formal ethical assessment was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article were accessed from World Health Organization COVID-19 situation reports and website of the Humanitarian Data Exchange. The corresponding author has no right to share the data.